دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy
Yao Wang, MD, PHD, a, * Haojie Zhu, MD,b, * Xiaofeng Hou, MD,a Zhao Wang, MD, PHD, b Fengwei Zou, MD,c Zhiyong Qian, MD, PHD, a Yongyue Wei, MD, PHD, d Xiang Wang, BS C,d Longyao Zhang, MD,d Xiaofei Li, MD, b Zhimin Liu, MD, b Siyuan Xue, MD,a Chaotong Qin, MD, a Jiaxin Zeng, MD, a Hui Li, MD,b Hongping Wu, MD, a Hong Ma, MD,a Kenneth A. Ellenbogen, MD,e Michael R. Gold, MD, PHD, f Xiaohan Fan, MD, P HD, b Jiangang Zou, MD, PHD, a,g on behalf of the LBBP-RESYNC Investigators
doi : 10.1016/j.jacc.2022.07.019
Volume 80, Issue 13, 27 September 2022, Pages 1205-1216
Left bundle branch pacing (LBBP) is the most rapidly growing conduction system pacing technique that is capable of correcting intrinsic left bundle branch block (LBBB). As such, it is potentially an optimal alternative to cardiac resynchronization therapy (CRT) with biventricular pacing (BiVP).
Left Bundle Branch Pacing for Cardiac Resynchronization: Are We Ready for a Leap of Faith?
Pugazhendhi Vijayaraman, MD, Syeda Atiqa Batul, MD
doi : 10.1016/j.jacc.2022.07.018
Volume 80, Issue 13, 27 September 2022, Pages 1217-1219
Abbreviated Antiplatelet Therapy After Coronary Stenting in Patients With Myocardial Infarction at High Bleeding Risk
Pieter C. Smits, MD, PHD, a Enrico Frigoli, MD,b Pascal Vranckx, MD, PH D, c,d Yukio Ozaki, MD, P HD, e Marie-Claude Morice, MD,f Bernard Chevalier, MD, g Yoshinobu Onuma, MD, PHD, h Stephan Windecker, MD,i Pim A.L. Tonino, MD, PHD, j Marco Roffi, MD, k Maciej Lesiak, MD, l Felix Mahfoud, MD,m Jozef Bartunek, MD, PHD, n David Hildick-Smith, MD, PH D, o Antonio Colombo, MD, p Goran Stankovic, MD, P HD, q Andrés Iñiguez, MD, PHD, r Carl Schultz, MD, PH D, s Ran Kornowski, MD,t Paul J.L. Ong, MD, PHD, u Mirvat Alasnag, MD, PHD, v Alfredo E. Rodriguez, MD, P HD, w Valeria Paradies, MD,a Petr Kala, MD, P HD, x Sasko Kedev, MD, PHD, y Amar Al Mafragi, MD,z Willem Dewilde, MD, PH D, aa Dik Heg, PHD, b Marco Valgimigli, MD, PH D, bb on behalf of the MASTER DAPT Investigators*
doi : 10.1016/j.jacc.2022.07.016
Volume 80, Issue 13, 27 September 2022, Pages 1220-1237
The optimal duration of antiplatelet therapy (APT) after coronary stenting in patients at high bleeding risk (HBR) presenting with an acute coronary syndrome remains unclear.
Post-PCI Antithrombotic Treatment With High Bleeding Risk
Scott Kinlay, MBBS, P HD
doi : 10.1016/j.jacc.2022.07.015
Volume 80, Issue 13, 27 September 2022, Pages 1238-1240
Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention
Prakash Krishnan, MD, a Serdar Farhan, MD, a Peter Schneider, MD, b, * Haroon Kamran, MD,a Osamu Iida, MD,c Marianne Brodmann, MD, d Antonio Micari, MD,e Ravish Sachar, MD,f Kasuki Urasawa, MD,g Dierk Scheinert, MD,h Kenji Ando, MD,i Arthur Tarricone, DPM, a Gheorghe Doros, PHD, j,k Gunnar Tepe, MD, l Hiroyoshi Yokoi, MD,m John Laird, MD,n Thomas Zeller, MD
doi : 10.1016/j.jacc.2022.06.043
Volume 80, Issue 13, 27 September 2022, Pages 1241-1250
Drug-coated balloons (DCB) are frequently used to treat femoropopliteal artery disease. However, patency loss occurs in ≥10% of patients within 12 months posttreatment with poor understanding of the underlying mechanisms.
Drug-Coated Balloon Failure Following Femoro-Popliteal Intervention: Where to Draw the Line?∗
Yasar Sattar, MD, a Herbert D. Aronow, MD, MPH,b Mahboob Alam, MD
doi : 10.1016/j.jacc.2022.08.002
Volume 80, Issue 13, 27 September 2022, Pages 1251-1253
Coronary Intervention Guided by Quantitative Flow Ratio vs Angiography in Patients With or Without Diabetes
Zening Jin, MD, a Bo Xu, MBBS, b,c Xingsheng Yang, MD, a Ruofei Jia, MD,a Shuai Meng, MD, a Hongyu Hu, MD, a Yue Deng, MD,b Xiaojing Cao, MD, a Yang Ruan, MD, a Jing Han, MD,a Jian Liu, MD,d Xinkai Qu, MD, e Yujie Zhou, MD, f Jian’an Wang, MD,g Guosheng Fu, MD, h Bo Yu, MD, i Yang Wang, MS C,j Changdong Guan, MS C, b Lei Song, MD,b Shengxian Tu, P HD, k Shubin Qiao, MD,b Gregg W. Stone, MD,l on behalf of the FAVOR III China Study Group
doi : 10.1016/j.jacc.2022.06.044
Volume 80, Issue 13, 27 September 2022, Pages 1254-1264
The clinical utility of the quantitative flow ratio (QFR), a novel angiography-based index for the functional assessment of coronary stenoses, has recently been demonstrated in patients undergoing percutaneous coronary intervention (PCI).
Does Diabetes Affect Angiographically Derived (QFR) Translesional Physiology?: Looking at the FAVOR III Diabetic Subset
Morton J. Kern, MD, MSCAI, Arnold H. Seto, MD, MPA
doi : 10.1016/j.jacc.2022.07.020
Volume 80, Issue 13, 27 September 2022, Pages 1265-1267
Athletic Activity for Patients With Hypertrophic Cardiomyopathy and Other Inherited Cardiovascular Diseases: JACC Focus Seminar 3/4
Christopher Semsarian, MBBS, PH D, MPH,a,b,c Belinda Gray, MBBS, P HD, b,c Kristina H. Haugaa, MD, PH D, d,e Rachel Lampert, MD, f Sanjay Sharma, BS C, MD, g Jason C. Kovacic, MBBS, PHD
doi : 10.1016/j.jacc.2022.07.013
Volume 80, Issue 13, 27 September 2022, Pages 1268-1283
As explored throughout this JACC Focus Seminar series, participation in regular exercise offers significant positive benefits for cardiovascular health. However, patients with underlying inherited cardiovascular diseases, such as hypertrophic cardiomyopathy, have historically been restricted from sports participation because of the risk of sudden cardiac death.
Aortic Tissue Analysis in Turner Syndrome
*Bruno Donadille, MD Alexander Valent, MD, PhD Kisaki Amemiya, MD, PhD Nicolas Rive le Gouard, MD Laurence Iserin, MD Paul Achouh, MD, PhD Tatiana Lecot-Connan, MD Patrick Bruneval, MD
doi : 10.1016/j.jacc.2022.07.017
Volume 80, Issue 13, 27 September 2022, Pages 1284-1285
POTS May Be Underestimated in Post-COVID Assessments
Mitchell G. Miglis, MD Lauren E. Stiles, JD *Satish R. Raj, MD MSCI
doi : 10.1016/j.jacc.2022.04.068
Volume 80, Issue 13, 27 September 2022, Page e103
Reply: POTS May Be Underestimated in Post-COVID Assessments
Sameer M. Jamal, MD David B. Landers, MD Taya V. Glotzer, MD Jana Tancredi, RN, MA/MSN Steven M. Hollenberg, MD
doi : 10.1016/j.jacc.2022.08.720
Volume 80, Issue 13, 27 September 2022, Page e105
